The Journal of Cancer Biology, Therapeutics and Clinical Oncology welcomes original, high-quality contributions from researchers, clinicians, and professionals working across the full spectrum of cancer science and clinical oncology. To maintain clarity and consistency throughout the editorial and publication process, authors are requested to carefully follow the submission guidelines outlined below.

Manuscript Categories

The journal accepts a wide range of manuscript types including original research articles, systematic reviews, clinical studies, brief reports, case reports, methodology papers, technical notes, perspectives, and letters to the editor. All submissions must be original, unpublished, and not under consideration by any other journal.

Manuscript Preparation

Authors should prepare their manuscripts using clear and concise language. Manuscripts must be submitted in English and formatted according to the following structure:

Title Page
The title page should include the manuscript title, the full names and affiliations of all authors, the corresponding author's email address, and a short running title (not exceeding 50 characters).

Abstract
All articles must include an abstract of no more than 300 words. The abstract should summarize the background, methods, results, and conclusions of the study. Avoid abbreviations and references in the abstract.

Keywords
Provide 4 to 6 relevant keywords that reflect the core content of the manuscript. These will assist in indexing and searchability.

Main Text
The main text of original research articles should typically be divided into the following sections: Introduction, Materials and Methods, Results, Discussion, and Conclusion. Subheadings may be used where appropriate to improve clarity.

References
All references should follow APA citation style. Authors are responsible for ensuring the accuracy and completeness of all references. In-text citations should include the author's surname and year of publication. The reference list should appear at the end of the manuscript and be formatted with a hanging indent.

Figures and Tables
All figures and tables must be cited in the text and numbered consecutively in the order of appearance. Each figure and table should include a descriptive caption. Figures should be high resolution (minimum 300 dpi) and submitted as separate files if possible.

Ethical Considerations
For studies involving human participants or animals, authors must include a statement confirming that all necessary ethical approvals were obtained and that procedures followed relevant institutional and international guidelines. Informed consent must be obtained for human studies where applicable.

Conflicts of Interest
Authors must disclose any potential conflicts of interest that could influence the work reported in the manuscript. If there are no conflicts to declare, authors should state, “The authors declare no conflict of interest.”

Funding Information
Authors should provide details of all funding sources that supported the research. If no external funding was received, this should be clearly stated.

Acknowledgments
Authors may include acknowledgments to individuals, institutions, or agencies that provided non-financial support for the work, such as assistance in data collection, technical help, or administrative support.

Supplementary Material
Supporting datasets, multimedia files, or extended tables may be submitted as supplementary material. These will be published alongside the article and made freely available.

Plagiarism and Originality
All manuscripts are screened for plagiarism using standard software. Submissions must be original and not plagiarized in whole or in part. Manuscripts found to contain significant overlap with previously published work will be rejected.

Peer Review Process
All submissions undergo a rigorous peer review process to ensure the integrity and quality of published content. Manuscripts are evaluated by at least two independent reviewers, and authors may be asked to revise their work based on reviewer feedback. Final decisions are made by the editorial board based on reviewer recommendations and overall merit.

Copyright and Licensing
Upon acceptance, authors will be required to sign a copyright agreement. All articles are published under an open access license, allowing for free distribution and reuse with appropriate attribution, in accordance with the Creative Commons Attribution License (CC BY).

Article Processing Charges (APC)
The Journal of Cancer Biology, Therapeutics and Clinical Oncology operates under an open access model, ensuring that all published articles are freely accessible to the global scientific community without subscription barriers. To support the costs associated with editorial processing, peer review, online hosting, long-term archiving, and other essential publishing services, authors are required to pay an Article Processing Charge (APC) upon acceptance of their manuscript. The APC amount will be communicated to the authors once their paper is accepted for publication in the journal. There are no additional fees for color figures, supplementary data, or corrections. Fee waivers or discounts may be considered in certain cases of financial hardship or for authors from low-income countries, at the discretion of the editorial office.

Submission Process
Manuscripts should be submitted electronically through the journal’s online submission portal. Authors are encouraged to ensure that their submission is complete and that all required sections are included prior to final submission. The editorial office will acknowledge receipt and keep authors informed throughout the review and publication stages.

Final Note to Authors
The Journal of Cancer Biology, Therapeutics and Clinical Oncology is committed to fostering scientific dialogue and supporting advancements in cancer research and clinical practice. We encourage authors to adhere to these guidelines closely to ensure a smooth review and publication process. By maintaining clarity, transparency, and academic rigor, we aim to build a reliable and respected platform for the global oncology community.